FOXP3+ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNF α agents

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Guidi, Luisa ^a   Felice, Carla ^a   Procoli, Annabella ^a   Bonanno, Giuseppina ^a   Martinelli, Enrica ^a   Marzo, Manuela ^a   Mocci, Giammarco ^a   Pugliese, Daniela ^a   Andrisani, Gianluca ^a   Danese, Silvio ^b   De Vitis, Italo ^a   Papa, Alfredo ^a   Armuzzi, Alessandro ^a   Rutella, Sergio ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; ENTERITIS; FEMALE; FLOW CYTOMETRY; HUMAN; INTESTINE BIOPSY; LAMINA PROPRIA; MALE; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; COLON; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MUCOSA; PATHOLOGY; YOUNG ADULT; DRUG ANTAGONISM; INFLAMMATORY BOWEL DISEASE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLON; CROHN DISEASE; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MUCOUS MEMBRANE; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84884220285     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/286368     Document Type: Article

References (37)

1. Danese S., Fiorino G., Rutella S., Regulatory T-cell therapy for Crohn's disease: in vivo veritas. Gastroenterology 2012 143 5 1135 1138
2. + T cells with regulatory properties from human blood. The Journal of Experimental Medicine 2001 193 11 1303 1310 2-s2.0-0035806244 10.1084/jem.193.11.1303
3. +CD25 bright T cells in human intestinal lamina propria as regulatory cells. Journal of Immunology 2004 173 5 3119 3130 2-s2.0-4344682025
4. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 5609 1057 1061 2-s2.0-0347785480 10.1126/science.1079490
5. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. International Immunology 1993 5 11 1461 1471 2-s2.0-0027517545
6. + T cells. Journal of Experimental Medicine 1993 178 1 237 244 2-s2.0-0027163182
7. + regulatory cells that control intestinal inflammation. The Journal of Experimental Medicine 2000 192 2 295 302 2-s2.0-0034679567 10.1084/jem.192.2.295
8. + regulatory T cells. Journal of Immunology 2003 170 8 3939 3943 2-s2.0-0037446531
9. Blanco Quirós A., Arranz Sanz E., Bernardo Ordiz D., Garrote Adrados J. A., From autoimmune enteropathy to the IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) syndrome. Allergologia et Immunopathologia 2009 37 4 208 215 2-s2.0-70349747028 10.1016/j.aller.2009.04. 002
10. + regulatory T cells: lessons from mouse models and implications for human disease. Diabetes/Metabolism Research and Reviews 2009 25 3 208 218 2-s2.0-65649129352 10.1002/dmrr.945
11. Costantino C. M., Baecher-Allan C., Hafler D. A., Multiple sclerosis and regulatory T cells. Journal of Clinical Immunology 2008 28 6 697 706 2-s2.0-56649117451 10.1007/s10875-008-9236-x
12. + regulatory T cells in human lupus erythematosus. Archives of Dermatological Research 2009 301 1 71 81 2-s2.0-58149151240 10.1007/s00403-008-0891-9
13. Sarkar S., Fox D. A., Regulatory T cell defects in rheumatoid arthritis. Arthritis and Rheumatism 2007 56 3 710 713 2-s2.0-33947174775 10.1002/art.22415
14. + T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology 2009 219 3 250 258 2-s2.0-70350336844 10.1159/000238305
15. Desreumaux P., Foussat A., Allez M., Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 2012 143 5 1207 1217
16. Leso V., Leggio L., Armuzzi A., Gasbarrini G., Gasbarrini A., Addolorato G., Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. European Journal of Gastroenterology and Hepatology 2010 22 7 779 786 2-s2.0-77953975086 10.1097/MEG.0b013e328331b654
17. Malaviya A. P., Ostör A. J., Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology 2012 20 2 59 69
18. Kim I. H., West C. E., Kwatra S. G., Comparative efficacy of biologics in psoriasis: a review. American Journal of Clinical Dermatology 2012 13 6 365 374
19. Ehrenstein M. R., Evans J. G., Singh A., Moore S., Warnes G., Isenberg D. A., Mauri C., Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF α therapy. The Journal of Experimental Medicine 2004 200 3 277 285 2-s2.0-3543140687 10.1084/jem.20040165
20. Nadkarni S., Mauri C., Ehrenstein M. R., Anti-TNF α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF β The Journal of Experimental Medicine 2007 204 1 33 39 2-s2.0-33846446041 10.1084/jem.20061531
21. Li Z., Arijs I., De Hertogh G., Vermeire S., Noman M., Bullens D., Coorevits L., Sagaert X., Schuit F., Rutgeerts P., Ceuppens J. L., Van Assche G., Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflammatory Bowel Diseases 2010 16 8 1299 1310 2-s2.0-77955747724 10.1002/ibd.21229
22. Di Sabatino A., Biancheri P., Piconese S., Rosado M. M., Ardizzone S., Rovedatti L., Ubezio C., Massari A., Sampietro G. M., Foschi D., Porro G. B., Colombo M. P., Carsetti R., MacDonald T. T., Corazza G. R., Peripheral regulatory T cells and serum transforming growth factor- β: relationship with clinical response to infliximab in Crohn's disease. Inflammatory Bowel Diseases 2010 16 11 1891 1897 2-s2.0-78249240373 10.1002/ibd.21271
23. + regulatory T cells in inflammatory bowel diseases. Inflammatory Bowel Diseases 2011 17 1 160 170 2-s2.0-78650080500 10.1002/ibd.21308
24. Grundström J., Linton L., Thunberq S., Altered immunoregulatory profile during anti-tumor necrosis factor treatment of patients with inflammatory bowel disease. Clinical and Experimental Immunology 2012 169 2 137 147
25. Veltkamp C., Anstaett M., Wahl K., Möller S., Gangl S., Bachmann O., Hardtke-Wolenski M., Länger F., Stremmel W., Manns M. P., Schulze-Osthoff K., Bantel H., Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNF α treatment. Gut 2011 60 10 1345 1353 2-s2.0-80052573212 10.1136/gut.2010.217117
26. + CD25high T cells in inflammatory bowel disease. Gastroenterology 2005 128 7 1868 1878 2-s2.0-20444434616 10.1053/j.gastro.2005.03.043
27. + regulatory T cells in Crohn's disease. Clinical Immunology 2007 125 3 281 290 2-s2.0-36249014365 10.1016/j.clim.2007.08.003
28. + CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflammatory Bowel Diseases 2006 12 6 447 456 2-s2.0-33745275219 10.1097/00054725-200606000-00003
29. + regulatory T cells in children affected by Crohn's disease. Immunology 2008 125 2 178 183 2-s2.0-51249084103 10.1111/j.1365-2567.2008.02839.x
30. Best W. R., Becktel J. M., Singleton J. W., Kern F. Jr., Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976 70 3 439 444 2-s2.0-0017227303
31. Rachmilewitz D., Barbier F., Defrance P., De Reuck M., Devis G., DeVos M., Elewaut A., Potvin P. H., Rutgeerts P., Vanheuverzwyn R., Van Trappen G., Bigard M., Camatte R., Cerf M., Colin R., Cortot A., Coumaros D., Gastard J., Labayle D., Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. British Medical Journal 1989 298 6666 82 86 2-s2.0-0024587677
32. Bonanno G., Mariotti A., Procoli A., Indoleamine 2, 3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine 2012 10 247 263
33. Kugathasan S., Saubermann L. J., Smith L., Kou D., Itoh J., Binion D. G., Levine A. D., Blumberg R. S., Fiocchi C., Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007 56 12 1696 1705 2-s2.0-36749038197 10.1136/gut.2006.116467
34. + regulatory T cells. Rheumatology International 2013 33 2 381 388 2-s2.0-84858736915 10.1007/s00296-012-2365-9
35. + CD25high T-regulatory cells. Blood 2006 108 1 253 261 2-s2.0-33646370647 10.1182/blood-2005-11-4567
36. Dige A., Hvas C. L., Deleuran B., Kelsen J., Bendix-Struve M., Dahlerup J. F., Agnholt J., Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells. Scandinavian Journal of Gastroenterology 2011 46 10 1206 1214 2-s2.0-80052906811 10.3109/00365521.2011.603157
37. Spurio F. F., Aratari A., Margagnoni G., Doddato M. T., Papi C., Early treatment in Crohn's disease: Do we have enough evidence to reverse the therapeutic pyramid? Journal of Gastrointestinal and Liver Diseases 2012 21 1 67 73 2-s2.0-84858810150